

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078705253

N/A

**COMPONENT®**  
BRAND IMPLANTS

**VetLife®**

# TE-200 WITH Tylan®

## FOR STEERS AND HEIFERS

fed in confinement for slaughter

trenbolone acetate 200 mg and estradiol

USP 20 mg with 29 mg tylosin tartrate

as a local antibacterial



## 20 dose CARTRIDGE BELT\*

### For Use In Animals Only

Each CARTRIDGE BELT holds 20 doses of COMPONENT® TE-200 with Tylan Implants. Each dose of 11 pellets consists of 10 pellets containing a total of 200 mg of trenbolone acetate and 20 mg estradiol plus 1 pellet containing 29 mg tylosin tartrate as a local antibacterial. COMPONENT® TE-200 Implants are recommended for use in steers and heifers fed in confinement for slaughter for INCREASED RATE OF WEIGHT GAIN AND IMPROVED FEED EFFICIENCY.

**INDICATIONS FOR USE:** This product contains trenbolone acetate and estradiol for increased rate of weight gain and improved feed efficiency in a slow-release delivery system. Do not use in veal calves. Effectiveness and animal safety in veal calves have not been established.

**NOTE:** COMPONENT® TE-200 is not better for increased average daily gain or improved feed efficiency than COMPONENT® TE-H (140 mg trenbolone acetate / 14 mg estradiol) in heifers fed in confinement for slaughter. Studies have demonstrated that administration of COMPONENT® TE-200 can result in decreased marbling scores when compared to non-implanted steers and heifers.

**DOSAGE:** Administer 1 implant per animal according to the following instructions.

**GENERAL INSTRUCTIONS:** Study the instructions which should be followed carefully at all times, avoiding short cuts. Skin infection can be avoided by properly preparing implant site and implanter. During fly season use fly repellent on implant site. One designated team member should always do the implanting. Cleanliness of hands and instruments is important at all times.

### WARNING

**Not to be used in animals intended for subsequent breeding, or in dairy animals.** Implant one dose — 11 pellets (entire contents of one cartridge cell) — in the ear subcutaneously. Any other site of implantation is in violation of Federal Law. DO NOT attempt to salvage implantation site for animal feed or human food.



**A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.**

**RESTRICTED DRUG — USE ONLY AS DIRECTED (CALIFORNIA) —  
FOR USE IN ANIMALS ONLY — NOT FOR HUMAN USE —  
KEEP OUT OF REACH OF CHILDREN**

### IMPLANTING INSTRUCTIONS:


#### Loading the Implanter

Load the implanter following the instructions supplied with each implanter.



### Restrain the Animal

Speed of implantation as well as safety of handlers is best achieved by restraining animal in a squeeze chute using head restraint. When implanting horned cattle, better control is obtained with additional use of nose tongs.




### Prepare the Implant Site

Scrub the back side of the ear (implant site) with a piece of clean absorbent cotton which has been soaked with topical germicidal solution. Follow manufacturer's directions on germicide for correct strength and preparation of solution. Avoid getting disinfectant in animal's eyes.



### Where to Implant

The full contents of one cartridge cell should be implanted beneath the skin on the back side of the middle one-third of the ear illustrated in the drawing. The implant must not be closer to the head than the edge of the auricular cartilage ring farthest from the head. The location for insertion of the needle is a point toward the tip of the ear at least a needle length away from the intended deposition site. Avoid injuring the large arteries, veins and cartilage of the ear.



### Insert the Needle

With one hand firmly grasp the ear. With the other hand insert needle point through the skin and ease forward on a lateral plane until the entire length of the needle is under the skin.

### Implant the Pellets

After inserting the needle fully in the correct implant position, squeeze the trigger fully as the needle is withdrawn from the ear. This properly deposits the implant in the needle track. This procedure should prevent breakage or crushing of pellets if otherwise forced into contact with tough fibrous-tissue underlying the skin. The length and total contact area of a single dose are designed to permit absorption of the hormones after implantation to stimulate good weight gain. Broken or crushed pellets may interfere with rates of gain.

### Clean the Needle

Clean the planter needle with alcohol or a properly diluted germicidal solution prior to implanting the next animal.

### Storage Conditions

Store in a refrigerator (2°-8°C; 36°-46°F) and protect from sunlight. Use before the expiration date printed on the foil pouch.

ANADA 200-346, Approved by FDA

**Manufactured by a non-sterilizing process.**

\*U.S. Patent No. 4,531,938

COMPONENT TE-200 with Tylan is covered by U.S. Patent No. 5,874,098

COMPONENT is a registered trademark of Ivy Animal Health, Inc.

Tylan is a registered trademark of Eli Lilly and Company.

Manufactured for **VetLife** by Ivy Laboratories • Overland Park, KS 66214, USA

VetLife and Ivy Laboratories are divisions of Ivy Animal Health, Inc.



# SAFETY DATA SHEET

## 1. Identification

<b>Product identifier</b>	<b>Component TE-H, TE-IH, TE-100, and TE-200 Implants with Tylan</b>
<b>Other means of identification</b>	
<b>Item Code</b>	AH0342, AH0513, AH0515, AH0511
<b>Synonyms</b>	Component TE-H Implant with Tylan * Component TE-IH Implant with Tylan * Component TE-100 Implant with Tylan * Component TE-200 Implant with Tylan
<b>Recommended use</b>	Veterinary Pharmaceutical
<b>Recommended restrictions</b>	None known.
<b>Manufacturer/Importer/Supplier/Distributor information</b>	
<b>Company Name</b>	Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 US
<b>Phone:</b>	1-877-Elanco1 (1-877-352-6261)
<b>Emergency Telephone:</b>	Elanco Product Technical Support / Human or Animal Exposure Reporting: 1-888-545-5973
<b>Email:</b>	elanco_sds@elanco.com
<b>Transportation Emergency Telephone:</b>	CHEMTREC: 1-800-424-9300 (Outside U.S. 1-703-527-3887)

## 2. Hazard(s) identification

<b>Physical hazards</b>	Not classified.	
<b>Health hazards</b>	Serious eye damage/eye irritation	Category 2B
	Sensitization, respiratory	Category 1
	Sensitization, skin	Category 1
	Carcinogenicity	Category 1A
	Reproductive toxicity	Category 1A
	Reproductive toxicity	Effects on or via lactation
<b>OSHA defined hazards</b>	Not classified.	
<b>Label elements</b>		



<b>Signal word</b>	Danger
<b>Hazard statement</b>	
H317	May cause an allergic skin reaction.
H320	Causes eye irritation.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H350	May cause cancer.
H360	May damage fertility or the unborn child.
H362	May cause harm to breast-fed children.
<b>Precautionary statement</b>	
<b>Prevention</b>	
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P261	Avoid breathing dust/fume/gas/mist/vapors/spray.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves/protective clothing/eye protection/face protection.  
P285 In case of inadequate ventilation wear respiratory protection.

#### Response

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
P304 + P341 IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308 + P313 IF exposed or concerned: Get medical advice/attention.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.  
P337 + P313 If eye irritation persists: Get medical advice/attention.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.  
P363 Wash contaminated clothing before reuse.

#### Storage

P405 Store locked up.

#### Disposal

P501 Dispose of contents/container in accordance with local/regional/national/international regulations.

**Hazard(s) not otherwise classified (HNOC)** None known.

**Supplemental information** None.

### 3. Composition/information on ingredients

#### Mixtures

Chemical name	Common name and synonyms	CAS number	%
Trenbolone Acetate		10161-34-9	50 - 59
Tylosin Tartrate	Tylosin, (2R,3R)-2,3-dihydroxybutanedioate (salt) LSN 029510	1405-54-5	8 - 19
Estradiol		50-28-2	5 - 6
Other components below reportable levels			20 - < 30

**Composition comments** This product consists of 4 to 10 Trenbolone Acetate and Estradiol Pellets packaged with a Tylosin Tartrate (Tylan) pellet as a single implant, with 20 implants encased in a single plastic cartridge belt that poses no exposure risk unless the belt is damaged.

### 4. First-aid measures

**Inhalation** Oxygen or artificial respiration if needed. Get medical attention immediately.

**Skin contact** Remove contaminated clothing and shoes. Get medical attention immediately.

**Eye contact** In case of eye contact, remove contact lens and rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention if irritation develops and persists.

**Ingestion** Call a physician or poison control center immediately. If conscious, give the victim plenty of water to drink. Never give anything by mouth to a victim who is unconscious or is having convulsions.

**Most important symptoms/effects, acute and delayed** May cause allergic skin reaction. May cause allergic respiratory reaction. Eye irritation. May cause cancer. May cause reproductive effects.

Intact implants are not considered hazardous under normal handling procedures. Caution should be used to avoid contact with the contents which contain trenbolone acetate and estradiol. In men, overexposure may lead to gynecomastia (breast tenderness, breast nodules or enlarged breasts), galactorrhea (secretion of milk), decreased libido and damage to the testes resulting in atrophy and infertility. In women, overexposure may cause menstrual irregularities (breakthrough bleeding, change in menstrual flow, spotting, amenorrhea), temporary infertility, breast changes (tenderness, enlargement, and secretion), hirsutism (excessive hair growth), and fluid retention. Increased breast size in boys and pseudoprecocious puberty in girls have been observed in children born to occupationally exposed women. Other effects of exposure to estradiol may include headache, nausea, vomiting, abnormal blood clotting, and increased incidence of cancer. An accelerated skeletal maturation, strong pigmentation of the sexual organs and a feminizing syndrome in boys has also been noted in children of parents who work in estrogen production.

**Indication of immediate medical attention and special treatment needed**

The estradiol may aggravate pre-existing estrogen-dependent neoplasias including malignancies of the female reproductive organs and breast, thromboembolic diseases, impaired liver or kidney function, and pregnancy.

**General information**

IF exposed or concerned: Get medical advice/attention. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance.

**5. Fire-fighting measures**

**Suitable extinguishing media**

Water. Carbon dioxide (CO<sub>2</sub>). Dry chemical.

**Unsuitable extinguishing media**

None known.

**Specific hazards arising from the chemical**

Hazardous decomposition products formed under fire conditions.

**Special protective equipment and precautions for firefighters**

Wear self-contained breathing apparatus and protective clothing.

**Fire fighting equipment/instructions**

Use water spray to cool unopened containers.

**Specific methods**

Use standard firefighting procedures and consider the hazards of other involved materials.

**General fire hazards**

No unusual fire or explosion hazards noted.

**6. Accidental release measures**

**Personal precautions, protective equipment and emergency procedures**

Keep unnecessary personnel away. Wear appropriate protective equipment and clothing during clean-up. Avoid inhalation of dust and contact with skin and eyes. See Section 8 of the SDS for Personal Protective Equipment.

**Methods and materials for containment and cleaning up**

If pellets remain intact, scoop or scrape up material into containers for disposal. If pellets are broken, contain dry material by lightly misting with water, followed by vacuuming. Vacuum material with appropriate dust collection filter in place. Be aware of potential for dust explosion when using electrical equipment. If vacuum is not available, lightly mist/wet material and remove by mopping or wet wiping.

Large spills due to traffic accidents, etc., should be reported immediately to CHEMTREC and Elanco Animal Health for assistance.

**Environmental precautions**

Avoid discharge into drains, water courses or onto the ground. Prevent spilled material from flowing onto adjacent land or into streams, ponds, or lakes.

**7. Handling and storage**

**Precautions for safe handling**

NOT INTENDED FOR HUMAN USE.

Do not handle until all safety precautions have been read and understood. Wear appropriate personal protective equipment. Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling.

**Conditions for safe storage, including any incompatibilities**

Keep containers tightly closed in a dry, cool and well-ventilated place. Store locked up.

**8. Exposure controls/personal protection**

**Occupational exposure limits**

**Lilly (LEG)**

**Components**

**Type**

**Value**

**Form**

Estradiol (CAS 50-28-2)

Excursion Limit

0.075 ug/m<sup>3</sup>

(30 minutes)

TWA (12hrs)

0.025 ug/m<sup>3</sup>

TWA (8hrs)

0.04 ug/m<sup>3</sup>

**Elanco OEL**

**Components**

**Type**

**Value**

Trenbolone Acetate (CAS 10161-34-9)

TWA (12hrs)

0.05 ug/m<sup>3</sup>

TWA (8hrs)

0.07 ug/m<sup>3</sup>

**Biological limit values**

No biological exposure limits noted for the ingredient(s).

**Exposure guidelines**

: 12 hour TWA <100 ug/m<sup>3</sup> (Tylosin Tartrate)

**Appropriate engineering controls**

Open handling is not recommended. Use appropriate control measures such as fume hood, ventilated enclosure, isolator (eg. glovebag, glovebox), or closed material transfer systems.

**Individual protection measures, such as personal protective equipment**

<b>Eye/face protection</b>	Wear safety glasses with side shields (or goggles).
<b>Skin protection</b>	
<b>Hand protection</b>	Chemical resistant gloves.
<b>Other</b>	Chemical-resistant gloves and impermeable body covering to minimize skin contact.
<b>Respiratory protection</b>	Select appropriate respirator for physical characteristics of material. Select respirator with appropriate protection factor. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the respirator.
<b>Thermal hazards</b>	Not available.
<b>General hygiene considerations</b>	<p>The intact implant is not considered hazardous under normal handling procedures.</p> <p>In a manufacturing setting, wear chemical-resistant gloves and body covering to minimize skin contact. If handled in a ventilated enclosure, as in a laboratory setting, respirator and goggles or face shield may not be required. Safety glasses are always required.</p> <p>Under normal use and handling conditions, wear goggles to protect eyes and wear impermeable gloves and protective equipment to avoid direct contact with skin. Wash thoroughly with soap and water after handling.</p>

**9. Physical and chemical properties**

<b>Appearance</b>	Cylindrical pellets packaged as an implant.
<b>Physical state</b>	Solid.
<b>Form</b>	Solid.
<b>Color</b>	Blue (Tylosin Tartrate)
	Pale yellow (Testosterone Propionate and Estradiol Benzoate)
<b>Odor</b>	Odorless
<b>Odor threshold</b>	No data available
<b>pH</b>	No data available.
<b>Melting point/freezing point</b>	No data available.
<b>Initial boiling point and boiling range</b>	No data available.
<b>Flash point</b>	No data available.
<b>Evaporation rate</b>	No data available.
<b>Flammability (solid, gas)</b>	No test data available.
<b>Upper/lower flammability or explosive limits</b>	
<b>Flammability limit - lower (%)</b>	No data available.
<b>Flammability limit - upper (%)</b>	No data available.
<b>Explosive limit - lower (%)</b>	No data available.
<b>Explosive limit - upper (%)</b>	No data available.
<b>Vapor pressure</b>	No data available.
<b>Vapor density</b>	No data available.
<b>Relative density</b>	No data available.
<b>Solubility(ies)</b>	
<b>Solubility (water)</b>	No data available.
<b>Partition coefficient (n-octanol/water)</b>	No data available.
<b>Auto-ignition temperature</b>	No data available.
<b>Decomposition temperature</b>	No data available.
<b>Viscosity</b>	No data available.
<b>Other information</b>	
<b>Density</b>	No data available.
<b>Explosive properties</b>	Not explosive.

<b>Oxidizing properties</b>	No oxidizing properties.
<b>Potential for dust explosion</b>	No data available.

## 10. Stability and reactivity

<b>Reactivity</b>	The product is stable and non-reactive under normal conditions of use, storage and transport.
<b>Chemical stability</b>	Material is stable under normal conditions.
<b>Possibility of hazardous reactions</b>	Hazardous polymerization does not occur.
<b>Conditions to avoid</b>	Contact with incompatible materials.
<b>Incompatible materials</b>	Strong oxidizing agents.
<b>Hazardous decomposition products</b>	Hazardous decomposition products formed under fire conditions.

## 11. Toxicological information

### Information on toxicological effects

#### Acute toxicity

Product	Species	Test Results
---------	---------	--------------

Component TE-H, TE-IH, TE-100, and TE-200 Implants with Tylan

#### Acute

##### Dermal

LD50 Rabbit 23040 mg/kg

##### Oral

LD50 Rat 71430 mg/kg

Components	Species	Test Results
------------	---------	--------------

Estradiol (CAS 50-28-2)

#### Acute

##### Dermal

LD Rabbit > 100 mg/kg No deaths or toxicity.

##### Oral

LD Rat > 500 mg/kg No deaths.

Trenbolone Acetate (CAS 10161-34-9)

##### Oral

LD50 Rat 5000 mg/kg

Tylosin Tartrate (CAS 1405-54-5)

#### Acute

##### Dermal

LD50 Rabbit > 2000 mg/kg

##### Inhalation

LC50 Rat > 600 mg/m<sup>3</sup>, 1 h

##### Oral

LD50 Rat > 6200 mg/kg

**Skin corrosion/irritation** Due to partial or complete lack of data the classification is not possible.

**Serious eye damage/eye irritation** Causes eye irritation. (Tylosin Tartrate) (cleared within 7 days)

#### Respiratory or skin sensitization

**Respiratory sensitization** May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Skin sensitization** May cause an allergic skin reaction.



**Germ cell mutagenicity** Negative in bacterial cells. Induced micronuclei but not chromosomal aberrations, aneuploidy, or sister chromatid exchanges in in-vitro human cell assays. Induced aneuploidy and unscheduled DNA synthesis but did not induce DNA strand breaks or sister chromatid exchanges in in-vitro rodent cell assays. Did not induce chromosomal aberrations in bone marrow cells of mice treated in-vivo. (Estradiol)

Results in genetic toxicity assays (in vitro): Negative (Trenbolone Acetate)

Mutagenic in one mammalian test system. Not mutagenic in bacterial cell tests and other mammalian cell tests. Unlikely to pose a genotoxic risk to man. (Tylosin Tartrate, as free base) Based on available data, the classification criteria are not met.

**Carcinogenicity** IARC Group 1 (sufficient evidence of carcinogenicity in humans).  
Estrogen-only menopausal therapy is carcinogenic to humans (Group 1)

IARC has not classified trenbolone acetate for carcinogenicity. NTP and OSHA have not listed trenbolone as a human carcinogen. Androgens as a class are considered probable human carcinogens.

Animal testing did not show any carcinogenic effects. (Tylosin Tartrate, as free base)

#### IARC Monographs. Overall Evaluation of Carcinogenicity

Estradiol (CAS 50-28-2) 1 Carcinogenic to humans.

#### OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

#### US. National Toxicology Program (NTP) Report on Carcinogens

Estradiol (CAS 50-28-2) Known To Be Human Carcinogen.

**Reproductive toxicity** May cause harm to breastfed babies. May damage fertility or the unborn child.

**Specific target organ toxicity - single exposure** Due to partial or complete lack of data the classification is not possible.

**Specific target organ toxicity - repeated exposure** Due to partial or complete lack of data the classification is not possible.

**Aspiration hazard** No aspiration toxicity classification

## 12. Ecological information

**Ecotoxicity** Very toxic to aquatic life with long lasting effects.

Components		Species	Test Results
Estradiol (CAS 50-28-2)			
<i>Chronic</i>			
Other	NOEC	Pseudokirchnerella subcapitata	>= 0.523 mg/l, 72 h
<b>Aquatic</b>			
<i>Acute</i>			
Algae	EC50	Algae	> 3.1 mg/l, 72 h (Desmodesmus subspicatus)
Crustacea	EC50	Water flea (Daphnia magna)	2.87 mg/l, 48 h
Fish	LC50	Medaka, high-eyes (Oryzias latipes)	460 µg/l, 72 h
<i>Chronic</i>			
Crustacea	NOEC	Water flea (Daphnia magna)	0.2 mg/l, 48 h
Fish	LC50	Medaka, high-eyes (Oryzias latipes)	0.002 µg/l, 96 h
Tylosin Tartrate (CAS 1405-54-5)			
	EC50	Oats (Seedling)	140 mg/kg (Growth, as free base)
		Soybean (Seedling)	53 mg/kg (Growth, as free base)
		Tomato (Seedling)	43 mg/kg (Growth, as free base)
<i>Acute</i>			
	LC50	Duck (Mallard duck)	> 5000 mg/kg, 5 days (dietary, as free base)
		Quail (Bobwhite quail)	> 5000 mg/kg, 5 days (dietary, as free base)

Components		Species	Test Results
Other	EC50	Pseudokirchnerella subcapitata	0.22 mg/l (average specific growth rate) (as free base)
<i>Chronic</i>			
	LC50	Earthworms (Eisenia fetida)	> 102.6 mg/kg, 14 days
		Quail (Bobwhite quail)	> 2000 mg/kg, 14 days
<b>Aquatic</b>			
<i>Acute</i>			
Crustacea	EC50	Daphnia magna	> 300 mg/l (as free base)
Fish	LC50	Bluegill (Lepomis macrochirus)	> 300 mg/l (as free base)
		Rainbow Trout	> 300 mg/l (as free base)

#### LILLY AQUATIC EXPOSURE GUIDELINES:

##### Tylosin Tartrate

Acute LAEG (at the edge of the acute mixing zone): 220 µg/l

Chronic LAEG (at the edge of the chronic mixing zone): 99 µg/l

Drinking water LAEG (at the point where surface water is taken for drinking water): 36 µg/l

##### Estradiol

Drinking water LAEG (at the point where surface water is taken for drinking water): 0.0002 µg/l

Chronic LAEG (at the edge of the chronic mixing zone): 0.0009 µg/l

Acute LAEG (at the edge of the acute mixing zone): 0.009 µg/l

**Persistence and degradability** No data is available on the degradability of this product.

**Bioaccumulative potential** The product contains potentially bioaccumulating substances.

##### Partition coefficient n-octanol / water (log Kow)

Estradiol 4.01  
Tylosin Tartrate 17, (pH 7)  
17, (pH 9)  
5, (pH 5)

**Mobility in soil** Soil degradation half-life (100 ppm): 62 days (tylosin factor A); 37 days (tylosin factor D)  
Soil degradation half-life (1 mg/kg; 4 soils): 50.3 to 105 days  
Leaching in soil column: none

##### Adsorption

###### Soil/sediment sorption - log Koc

Tylosin Tartrate 1652 Silt Loom (pH 5.7)  
200 Sandy Loom (pH 4.6)  
2233 Sandy Loom (pH 7.6)

**Other adverse effects** Not available.

### 13. Disposal considerations

**Disposal instructions** Dispose of contents/container in accordance with local/regional/national/international regulations.  
Do not allow this material to drain into sewers/water supplies.

### 14. Transport information

**General information** Effective January 1, 2015 by Special Provision, UN3077 and UN3082 when packaged in inner packages of 5L / 5 KG or less are not subject to the dangerous goods regulations.

#### DOT

Not regulated as dangerous goods.

#### IATA

**UN number** UN3077  
**UN proper shipping name** Environmentally hazardous substance, solid, n.o.s. (Trenbolone Acetate, Estradiol)  
**Transport hazard class(es)**  
**Class** 9  
**Subsidiary risk** -  
**Packing group** III  
**Environmental hazards** Yes  
**ERG Code** 9L  
**Special precautions for user** Not available.


**Other information**

**Passenger and cargo aircraft** Allowed with restrictions.  
**Cargo aircraft only** Allowed with restrictions.

**IMDG**

**UN number** UN3077  
**UN proper shipping name** ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Trenbolone Acetate, Estradiol)  
**Transport hazard class(es)**  
**Class** 9  
**Subsidiary risk** -  
**Packing group** III  
**Environmental hazards**  
**Marine pollutant** Yes  
**EmS** F-A, S-F  
**Special precautions for user** Not available.

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code** Not applicable.

**IATA; IMDG****Marine pollutant****15. Regulatory information**

**US federal regulations** This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.  
CERCLA/SARA Hazardous Substances - Not applicable.

One or more components are not listed on TSCA.

**Toxic Substances Control Act (TSCA)**

**TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)**

Not regulated.

**CERCLA Hazardous Substance List (40 CFR 302.4)**

Not listed.

**SARA 304 Emergency release notification**

Not regulated.

**OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)**

Not regulated.

## Superfund Amendments and Reauthorization Act of 1986 (SARA)

<b>Classified hazard categories</b>	Serious eye damage or eye irritation
	Respiratory or skin sensitization
	Carcinogenicity
	Reproductive toxicity

### SARA 313 (TRI reporting)

Not regulated.

### Other federal regulations

#### Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

#### Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

### US state regulations

#### California Proposition 65



**WARNING:** WARNING: This product contains a chemical known to the State of California to cause cancer and birth defects or other reproductive harm.

#### California Proposition 65 - CRT: Listed date/Carcinogenic substance

Estradiol (CAS 50-28-2)

Listed: January 1, 1988

#### California Proposition 65 - CRT: Listed date/Developmental toxin

Estradiol (CAS 50-28-2)

Listed: April 1, 1990

### International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

\*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

## 16. Other information, including date of preparation or last revision

**Issue date** 03-18-2015

**Revision date** 03-26-2019

**Version #** 04

### Disclaimer

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:

Elanco Animal Health  
0011+1-877-352-6261  
0011+1-800-428-4441